Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Tommaso Tedeschini"'
Autor:
Maria Rosaria Battista, Antonella Grigoletto, Tommaso Tedeschini, Antonella Cellucci, Fabrizio Colaceci, Ralph Laufer, Gianfranco Pasut, Annalise Di Marco
Publikováno v:
PLoS ONE, Vol 17, Iss 3 (2022)
Ciliary neurotrophic factor (CNTF) is a neurotrophic cytokine able to induce appetite reduction, weight loss and antidiabetic effects. However, its susceptibility to neutralizing anti-CNTF antibodies in patients hampered its use for treatment of huma
Externí odkaz:
https://doaj.org/article/275712289d7d46749feca52a20c48f5e
Autor:
Antonella Grigoletto, Gabriele Martinez, Daniela Gabbia, Tommaso Tedeschini, Michela Scaffidi, Sara De Martin, Gianfranco Pasut
Publikováno v:
Pharmaceutics, Vol 13, Iss 7, p 929 (2021)
Although selective tumor delivery of anticancer drugs has been sought by exploiting either passive targeting or by ligand-mediated targeting, a selective anticancer therapy remains an unmet medical need. Despite the advances which have been achieved
Externí odkaz:
https://doaj.org/article/3bdf0b18b69a4d7ca22374fce5e13484
Autor:
Maria Rosaria Battista, Antonella Grigoletto, Tommaso Tedeschini, Antonella Cellucci, Fabrizio Colaceci, Ralph Laufer, Gianfranco Pasut, Annalise Di Marco
Publikováno v:
PloS one. 17(3)
Ciliary neurotrophic factor (CNTF) is a neurotrophic cytokine able to induce appetite reduction, weight loss and antidiabetic effects. However, its susceptibility to neutralizing anti-CNTF antibodies in patients hampered its use for treatment of huma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18984018e339d77e1a28aa1365875f54
https://pubmed.ncbi.nlm.nih.gov/35316287
https://pubmed.ncbi.nlm.nih.gov/35316287
Autor:
Antonella Grigoletto, Y. Matsuno, Tommaso Tedeschini, M. Salvalaio, Gianfranco Pasut, B. Campara, Marino Bellini, Akira Suzuki, Hiroki Yoshioka
Publikováno v:
Journal of controlled release : official journal of the Controlled Release Society. 337
Antibody-drug conjugates (ADCs) are an established therapeutic entity in which potent cytotoxic drugs are conjugated to a monoclonal antibody. In parallel with the great emphasis put on novel site-specific bioconjugation technologies, future advancem
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fa9e48a97dbb8ef17547ec4e2a81a642
https://pubmed.ncbi.nlm.nih.gov/34329685
https://pubmed.ncbi.nlm.nih.gov/34329685
Autor:
Gabriele Martinez, Sara De Martin, Tommaso Tedeschini, Antonella Grigoletto, Michela Scaffidi, Gianfranco Pasut, Daniela Gabbia
Publikováno v:
Pharmaceutics
Pharmaceutics, Vol 13, Iss 929, p 929 (2021)
Volume 13
Issue 7
Pharmaceutics, Vol 13, Iss 929, p 929 (2021)
Volume 13
Issue 7
Although selective tumor delivery of anticancer drugs has been sought by exploiting either passive targeting or by ligand-mediated targeting, a selective anticancer therapy remains an unmet medical need. Despite the advances which have been achieved
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::90fee2cc49ac98f0bfb51c6ea2f767d9
http://hdl.handle.net/11577/3395464
http://hdl.handle.net/11577/3395464
Publikováno v:
WIREs Nanomedicine and Nanobiotechnology. 13
Polymer conjugation can be considered one of the leading approaches within the vast field of nanotechnology-based drug delivery systems. In fact, such technology can be exploited for delivering an active molecule, such as a small drug, a protein, or
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af1f401dd023f82aad411f0aba44380d
https://doi.org/10.1002/wnan.1689
https://doi.org/10.1002/wnan.1689